glp-1 cardiovascular outcomes trial results august 2025 The Big of a drug (Wegovy) to Reduce Major Events SGLT2 inhibitors and GLP-1 receptor

MedVi takes a more consultative approach, with clinician-directed protocol selection based on your health profile, goals, and medical history

GI side effects: - Nausea: reported at rates comparable to other GLP-1/GIP drugs - Vomiting: 26% of VK2735-treated subjects vs 10% on placebo higher than most competitors - Diarrhea and constipation: within the expected range for this drug class The vomiting rate is the main concern

These symptoms can indicate hypoglycaemia, particularly in individuals taking Ozempic in combination with insulin or sulfonylureas

JCSM Rapid Communications 2020;3(1):25-37

A better understanding of the microbiotagut interaction in IBD will be helpful in developing novel therapeutic and diagnostic options in the future